Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 1307083
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Tp73
Name: tumor protein p73
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Tp73affects localizationISOTP73 (Homo sapiens)6480464CTDCisplatin affects the localization of TP73 protein modified formPMID:21516125
Tp73decreases expressionISOTP73 (Homo sapiens)6480464CTDCisplatin results in decreased expression of TP73 mRNA; Cisplatin results in decreased expression of TP73 protein modified formPMID:21516125 PMID:21737676
Tp73decreases expressionISOTrp73 (Mus musculus)6480464CTDCisplatin results in decreased expression of TRP73 alternative formPMID:22002055
Tp73decreases response to substanceISOTrp73 (Mus musculus)6480464CTDTRP73 alternative form results in decreased susceptibility to CisplatinPMID:22002055
Tp73increases activityISOTP73 (Homo sapiens)6480464CTDCisplatin results in increased activity of TP73 proteinPMID:14678968
Tp73increases expressionISOTP73 (Homo sapiens)6480464CTDCisplatin results in increased expression of TP73 mRNA; Cisplatin results in increased expression of TP73 proteinPMID:17076661 PMID:20655883 PMID:21214929 PMID:21274007 PMID:37760451
Tp73increases expressionISOTrp73 (Mus musculus)6480464CTDCisplatin results in increased expression of TRP73PMID:22002055
Tp73increases phosphorylationISOTrp73 (Mus musculus)6480464CTDCisplatin results in increased phosphorylation of TRP73 proteinPMID:35219798
Tp73increases response to substanceISOTP73 (Homo sapiens)6480464CTDTP73 protein modified form results in increased susceptibility to Cisplatin; TP73 results in increased susceptibility to CisplatinPMID:20100536 PMID:21516125
Tp73multiple interactionsISOTP73 (Homo sapiens)6480464CTD[[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of BAX protein; [[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of FAS protein; [[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [[[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of BAX mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of BAX protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of FAS mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of FAS protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B mRNA; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in increased expression of TNFRSF10B protein; [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein; [Cisplatin co-treated with S63845] results in increased expression of TP73 mRNA; [Cisplatin co-treated with TP73 protein] results in increased expression of BAX protein; [Cisplatin co-treated with TP73 protein] results in increased expression of CDKN1A protein; [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in decreased expression of BCL2 protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in increased expression of BAX protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in increased expression of FAS protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in increased expression of PMAIP1 protein; [YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in increased expression of TNFRSF10B protein; calpeptin inhibits the reaction [Cisplatin results in decreased expression of TP73 protein modified form]; Cisplatin promotes the reaction [[TP73 protein binds to GRAMD4 promoter] which results in increased expression of GRAMD4 mRNA]; Cisplatin promotes the reaction [[TP73 protein binds to IL4R intron] which results in increased expression of IL4R mRNA]; Cisplatin results in increased localization of [PLK1 protein co-treated with TP73 protein]; MCL1 protein affects the reaction [Cisplatin results in increased expression of TP73 mRNA]; PLK1 protein inhibits the reaction [Cisplatin results in increased expression of TP73 protein]; RELA protein mutant form inhibits the reaction [Cisplatin results in decreased expression of TP73 mRNA]; S63845 promotes the reaction [Cisplatin results in increased expression of TP73 protein]; TP73 mutant form inhibits the reaction [RELA promotes the reaction [Cisplatin results in increased expression of PMAIP1 mRNA]]; TP73 protein modified form promotes the reaction [Cisplatin results in increased expression of BBC3 protein]; TP73 protein modified form promotes the reaction [Cisplatin results in increased expression of PMAIP1 protein]; TP73 protein promotes the reaction [Cisplatin results in increased expression of GRAMD4 mRNA]; TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin]; Wortmannin promotes the reaction [Cisplatin results in increased expression of TP73 protein]; YAP1 protein promotes the reaction [[Cisplatin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]PMID:14678968 PMID:20100536 PMID:20655883 PMID:20686837 PMID:21127500 PMID:21214929 PMID:21516125 PMID:21737676 PMID:37760451
Tp73multiple interactionsISOTrp73 (Mus musculus)6480464CTDImatinib Mesylate inhibits the reaction [Cisplatin results in increased phosphorylation of TRP73 protein]PMID:35219798
Go Back to source page   Continue to Ontology report